Targeted human-interferon fusion proteins

US10034919B2 · kind B2 · utility

Assignees

• VIB VZW · BE
• UNIVERSITEIT GENT · BE
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• Universite Montepellier 2 · FR
• Centre Hospitalier Regional Universitaire de Montpellier · FR
• UNIVERSITAT OSNABRUCK · DE

Inventors

• Jan Tavernier · Balegem, BE
• Gilles Uze · Montpellier, FR
• Guillaume Cartron · Juvignac, FR
• Franciane Paul · Montpellier, FR
• Jacob Piehler

Key dates

• Filing date: Sep 27, 2017
• Grant date: Jul 31, 2018
• Expiry date: Sep 27, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.